Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07447128 · ClinicalTrials.gov registry record · NA
Prospective Analysis of Arteriovenous Access (AVA) Use in Continuous Renal Replacement Therapy: A Feasibility Project
A NA study, sponsored by East Carolina University.
- Not yet
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07447128 is a NA study that has not yet begun recruiting, run by East Carolina University. The registered enrollment target is 50 participants.
The verdict
NCT07447128, a NA study, has not yet begun recruiting, sponsored by East Carolina University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study will test whether patients who already have a permanent dialysis access (an arteriovenous fistula or graft) can safely use that access for continuous dialysis (CRRT) while they are critically ill in the intensive care unit, instead of requiring a temporary central venous catheter. About 50 patients will participate. Researchers will monitor how well the access works, whether any complications occur, and whether there are differences between fistulas and grafts. The goal is to determine whether using a patient's existing dialysis access is a safe and practical option that could reduce the need for temporary catheters and their associated risks, such as infection and bleeding.
Interventions
- OTHER Cannulation of permanent dialysis access, for the purpose of delivering continuous renal replacement therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-07-27 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07447128
The ClinicalTrials.gov registry entry for NCT07447128 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is East Carolina University, which has 58 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannulation of permanent dialysis access, for the purpose of delivering continuous renal replacement therapy. is the first listed.
NCT07447128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07447128 about?
NCT07447128 is a clinical study titled "Prospective Analysis of Arteriovenous Access (AVA) Use in Continuous Renal Replacement Therapy: A Feasibility Project". This study will test whether patients who already have a permanent dialysis access (an arteriovenous fistula or graft) can safely use that access for continuous dialysis (CRRT) while they are critically ill in the intensive care unit, instead of requiring a temporary central venous catheter. About 5...
What is the current status of trial NCT07447128?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-07-27. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07447128?
The interventions under investigation include: Cannulation of permanent dialysis access, for the purpose of delivering continuous renal replacement therapy. (OTHER).
Who is sponsoring clinical trial NCT07447128?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.